Acromegaly Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics

Posted on
by

Acromegaly Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics
The Key Acromegaly Companies in the market include – Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics, Amryt Pharma/Chiasma, Recordati/Novartis Pharmaceuticals, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, Ipsen, and others.

 

DelveInsight’s “Acromegaly Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Acromegaly, offering comprehensive insights into the Acromegaly revenue trends, prevalence, and treatment landscape. The report delves into key Acromegaly statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Acromegaly therapies. Additionally, we cover the landscape of Acromegaly clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Acromegaly treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Acromegaly space.

 

Get a Free sample for the Acromegaly Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/acromegaly-market

 

Some of the key facts of the Acromegaly Market Report:

  • The Acromegaly market size was valued ~USD 1,300 million in 2023 and is expected to grow with a significant CAGR during the study period (2022-2036).

  • In January 2026, Camurus announced that the US Food and Drug Administration (FDA) had accepted for review the resubmitted New Drug Application (NDA) for CAM2029 (Oclaiz), an octreotide extended-release injection, for the treatment of patients with acromegaly. The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026.

  • In January 2026, Marea announced positive Phase I topline results for MAR002 in acromegaly, highlighting potential for best-in-class efficacy and a favorable dosing profile.

  • In December 2025, Debiopharm announced that the first patient had been randomized in the Phase III (OXTEND-03) clinical trial for adults with acromegaly who are currently maintained on somatostatin analogs.

  • In February 2026, Crinetics Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had adopted a positive opinion recommending the marketing authorization of PALSONIFY (paltusotine) for the treatment of adult patients with acromegaly. The opinion has been forwarded to the European Commission (EC), which will make the final approval decision.

  • According to estimates, the total acromegaly market size in 7MM was approximately USD 1,300 million in 2025, with the United States accounting for the largest share, and the market is projected to grow at a significant CAGR through 2036.

  • In 2025, among the EU4 and the UK, the UK held the largest market share, followed by Germany, while Spain accounted for the smallest share.

  • According to DelveInsight’s estimates, in 2025, the total number of diagnosed prevalent cases of acromegaly in the 7MM was ~59,000.

  • In the United States, acromegaly has an estimated incidence of ~2–11 new cases per million annually, with approximately 20,000–45,000 prevalent cases, though the true burden is likely underestimated due to underdiagnosis.

  • The total diagnosed prevalent cases of acromegaly in the United States were estimated at ~27,500 in 2025, and are projected to increase by 2036, driven by improved detection and greater disease awareness.

  • In the United States, ~95% of cases are attributed to pituitary adenomas, while only ~5% arise from non-pituitary sources, underscoring the dominant role of pituitary-origin disease.

  • Acromegaly demonstrates a slight female predominance (~51% vs. ~49% in males), with most patients diagnosed in their 40s to 50s, reflecting the slow and progressive nature of the disease.

  • In EU4 and the UK countries, Germany had the highest number of diagnosed prevalent cases, while Spain had the least.

  • Based on tumor size, acromegaly is classified into microadenoma and macroadenoma, which are key determinants of disease severity and treatment strategy.

  • Key Acromegaly Companies: Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics, Amryt Pharma/Chiasma, Recordati/Novartis Pharmaceuticals, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, Ipsen, and others.

  • Key Acromegaly Therapies: Paltusotine (PALSONIFY), CAM2029 (OCZYESA), Octreotide (MYCAPSSA), Debio 4126, ALXN2420, MAR002, MYCAPSSA (octreotide acetate), SIGNIFOR LAR (pasireotide), Paltusotine (CRN 00808), GHR-LRX, CAM2029 (octreotide subcutaneous depot), Lanreotide Autogel®, and others.

  • The Acromegaly market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acromegaly pipeline products will significantly revolutionize the Acromegaly market dynamics.

  • In 2023, the United States had the highest number of diagnosed prevalent cases of acromegaly in the 7MM, with approximately 27,000 cases, followed by Japan with around 9,000 cases.

  • In the United States, gender-specific cases of acromegaly in 2023 were approximately 13,000 in males and around 14,000 in females.

  • In the US, tumor size-specific cases of acromegaly in 2023 were approximately 75% for macroadenomas and 25% for microadenomas, with numbers expected to rise.

  • In the EU4 and the UK, tumor origin-specific cases of acromegaly in 2023 included approximately 20,300 cases from pituitary tumors and around 1,060 cases from non-pituitary tumors.

 

Acromegaly Overview

Acromegaly is a rare hormonal disorder that occurs when the pituitary gland produces too much growth hormone (GH), typically due to a benign tumor called a pituitary adenoma. This excess GH causes abnormal growth of bones and tissues, leading to enlarged hands, feet, and facial features. Symptoms can develop slowly over years, often resulting in delayed diagnosis. If untreated, acromegaly can lead to serious health complications, including diabetes, hypertension, arthritis, and cardiovascular disease. Treatments include surgery, medication, and radiation therapy to reduce GH levels and manage symptoms.

 

To Know in detail about the Acromegaly market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acromegaly Market Forecast

 

Acromegaly Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Acromegaly Epidemiology Segmentation:

The Acromegaly market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases of Acromegaly Occurrence

  • Tumor Origin-specific Diagnosed Prevalent Cases of Acromegaly

  • Gender-specific Diagnosed Prevalent Cases of Acromegaly

  • Tumor Size-specific Diagnosed Prevalent Cases of Acromegaly

  • Total Treated Cases of Acromegaly

 

Download the report to understand which factors are driving Acromegaly epidemiology trends @ Acromegaly Epidemiology Forecast

 

Acromegaly Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acromegaly market or expected to get launched during the study period. The analysis covers Acromegaly market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acromegaly Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Acromegaly Therapies and Key Companies

  • Paltusotine (PALSONIFY): Crinetics

  • CAM2029 (OCZYESA): Camurus

  • Octreotide (MYCAPSSA): Chiesi

  • Debio 4126: Debiopharm International SA

  • ALXN2420: AstraZeneca

  • MAR002: Marea Therapeutics

  • MYCAPSSA (octreotide acetate): Amryt Pharma/Chiasma

  • SIGNIFOR LAR (pasireotide): Recordati/Novartis Pharmaceuticals

  • Paltusotine (CRN 00808): Crinetics Pharmaceuticals

  • CAM2029 (octreotide subcutaneous depot): Camurus AB

  • GHR-LRX: Ionis Pharmaceuticals

  • Lanreotide A Autogel®: Ipsen

 

Discover more about therapies set to grab major Acromegaly market share @ Acromegaly Treatment Landscape

 

Acromegaly Market Drivers

  • Increasing Awareness and Early Diagnosis: Improved awareness among healthcare professionals and advancements in diagnostic techniques are facilitating earlier detection of acromegaly.

  • Advancements in Targeted Therapies: The development of novel somatostatin analogs, growth hormone receptor antagonists, and other targeted treatments is enhancing disease management.

  • Growing Adoption of Long-Acting Formulations: Long-acting injectable therapies improve patient convenience, adherence, and treatment outcomes, driving market growth.

  • Rising Healthcare Expenditure: Increased investments in endocrinology care and rare disease management are supporting access to advanced therapies.

 

Acromegaly Market Barriers

  • Rare Disease Prevalence: The relatively small patient population limits the overall market size and commercial opportunities.

  • Delayed Diagnosis: Acromegaly symptoms often develop gradually and may be mistaken for other conditions, leading to delayed diagnosis and treatment.

  • High Cost of Treatment: Advanced biologics and long-term therapy requirements can impose a significant financial burden on patients and healthcare systems.

  • Limited Access in Developing Regions: Inadequate healthcare infrastructure and limited availability of specialized endocrinology services may restrict treatment access.

  • Treatment-Related Side Effects: Certain therapies may be associated with gastrointestinal, metabolic, or injection-site adverse effects that can affect patient compliance.

 

Scope of the Acromegaly Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Acromegaly Companies: Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics, Amryt Pharma/Chiasma, Recordati/Novartis Pharmaceuticals, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, Ipsen, and others

  • Key Acromegaly Therapies: Paltusotine (PALSONIFY), CAM2029 (OCZYESA), Octreotide (MYCAPSSA), Debio 4126, ALXN2420, MAR002, MYCAPSSA (octreotide acetate), SIGNIFOR LAR (pasireotide), Paltusotine (CRN 00808), GHR-LRX, CAM2029 (octreotide subcutaneous depot), Lanreotide Autogel®, and others

  • Acromegaly Therapeutic Assessment: Acromegaly current marketed and Acromegaly emerging therapies

  • Acromegaly Market Dynamics: Acromegaly market drivers and Acromegaly market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Acromegaly Unmet Needs, KOL’s views, Analyst’s views, Acromegaly Market Access and Reimbursement

 

To know more about Acromegaly companies working in the treatment market, visit @ Acromegaly Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Acromegaly Market Report Introduction

2. Executive Summary for Acromegaly

3. SWOT analysis of Acromegaly

4. Acromegaly Patient Share (%) Overview at a Glance

5. Acromegaly Market Overview at a Glance

6. Acromegaly Disease Background and Overview

7. Acromegaly Epidemiology and Patient Population

8. Country-Specific Patient Population of Acromegaly

9. Acromegaly Current Treatment and Medical Practices

10. Acromegaly Unmet Needs

11. Acromegaly Emerging Therapies

12. Acromegaly Market Outlook

13. Country-Wise Acromegaly Market Analysis (2022–2036)

14. Acromegaly Market Access and Reimbursement of Therapies

15. Acromegaly Market Drivers

16. Acromegaly Market Barriers

17. Acromegaly Appendix

18. Acromegaly Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679 Source: https://www.delveinsight.com/report-store.php
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/